bpc-157 human clinical trial evidence review safety Peptide bpc-157 human clinical trials evidence
Description
NNMT's job: Take nicotinamide (a NAD+ precursor) and methylate it essentially tagging it for disposal
Very simple process
status under M3 (gene/cellular doping) or S0 is unclear and treated as high-risk
However, the lack of clinical trials means that there could potentially be serious BPC-157 side effects in humans, which remain unknown
